EFSA: Europe's independent science authority
The European Food Safety Authority (EFSA) is the independent scientific body that evaluates health claims for food supplements across the EU. When a claim is validated, it means independent experts have reviewed all available clinical evidence and confirmed a causal relationship between the substance and the claimed effect. LIPOSLIM™ is one of the very few formulas on the market built exclusively around actives that have cleared this demanding regulatory standard.
Glucomannan: the satiety fibre
Extracted from konjac root, a plant native to Southeast Asia, glucomannan is the only substance to have obtained the EFSA health claim for "contributing to weight loss in the context of an energy-restricted diet" (EFSA Opinion 2010 — condition ID 854). Its mechanism is mechanical: when mixed with water, it forms a viscous gel in the stomach that slows gastric emptying, prolongs satiety, and reduces carbohydrate absorption. LIPOSLIM™ contains 3 g per daily dose, the clinically validated threshold recognised by EFSA.
Chromium: master of blood sugar balance
Chromium (III) is an essential trace element for carbohydrate and lipid metabolism. EFSA has granted two validated claims: "chromium contributes to normal macronutrient metabolism" (ID 776) and "chromium contributes to the maintenance of normal blood glucose levels" (ID 777). By optimising insulin sensitivity, it reduces post-meal blood sugar spikes — the fluctuations that trigger cravings and fat storage. Stable blood sugar is the ideal physiological state for maintaining a healthy weight.
Garcinia HCA: the lipogenesis inhibitor
Hydroxycitric acid (HCA), extracted from Garcinia cambogia, acts through a precise biochemical mechanism: it inhibits ATP-citrate lyase, the key enzyme in de novo lipogenesis (fat synthesis from carbohydrates). While EFSA has not granted an official weight loss claim for HCA, a meta-analysis published in the Journal of Obesity (2011, doi:10.1155/2011/509038) documents significant body fat reduction at 12 weeks. BPC's philosophy: include actives backed by robust science, whether EFSA-validated or documented through peer-reviewed clinical studies.